<unk> , sold under the brand name Tafinlar & Rafinlar ( both by Novartis) among others, is a medication for the treatment of cancers associated with a mutated version of the gene BRAF.<unk>  acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth.<unk>  has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF (V600)-mutated metastatic melanoma.
Dabrafenib
Enasidenib
Ivosidenib
Tucatinib
Fostamatinib
Neratinib
Erdafitinib
Abrocitinib